Mirum Pharmaceuticals (NASDAQ:MIRM) Insider Sells $170,047.26 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) insider Joanne Quan sold 1,822 shares of the firm’s stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $93.33, for a total transaction of $170,047.26. Following the transaction, the insider directly owned 12,817 shares of the company’s stock, valued at approximately $1,196,210.61. This trade represents a 12.45% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Joanne Quan also recently made the following trade(s):

• On Tuesday, January 20th, Joanne Quan sold 6,911 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $90.27, for a total transaction of $623,855.97.

Mirum Pharmaceuticals Price Performance

Shares of MIRM opened at $94.29 on Monday. The business’s 50-day moving average is $77.33 and its two-hundred day moving average is $70.90. The company has a market capitalization of $4.85 billion, a P/E ratio of -109.64 and a beta of 0.48. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $36.88 and a fifty-two week high of $96.84. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.16 and a current ratio of 3.31.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.15. The firm had revenue of $133.01 million for the quarter, compared to the consensus estimate of $130.11 million. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The company’s revenue was up 47.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.30) earnings per share. Research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Sumitomo Mitsui Trust Group Inc. purchased a new position in shares of Mirum Pharmaceuticals in the fourth quarter valued at approximately $240,000. Wetzel Investment Advisors Inc. acquired a new position in Mirum Pharmaceuticals in the 4th quarter valued at $205,000. Palumbo Wealth Management LLC lifted its holdings in Mirum Pharmaceuticals by 19.8% in the 4th quarter. Palumbo Wealth Management LLC now owns 5,082 shares of the company’s stock valued at $401,000 after purchasing an additional 840 shares in the last quarter. Secure Asset Management LLC lifted its holdings in Mirum Pharmaceuticals by 4.0% in the 4th quarter. Secure Asset Management LLC now owns 50,384 shares of the company’s stock valued at $3,980,000 after purchasing an additional 1,943 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new stake in Mirum Pharmaceuticals during the 4th quarter worth $1,478,000.

Analyst Ratings Changes

MIRM has been the subject of several analyst reports. TD Cowen reiterated a “buy” rating on shares of Mirum Pharmaceuticals in a research note on Monday, January 12th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $130.00 price objective on shares of Mirum Pharmaceuticals in a report on Monday, December 8th. Evercore ISI reissued an “outperform” rating and set a $101.00 target price on shares of Mirum Pharmaceuticals in a research note on Tuesday, January 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research report on Thursday. Finally, Citizens Jmp upped their price target on Mirum Pharmaceuticals from $95.00 to $140.00 and gave the stock a “market outperform” rating in a report on Friday, December 19th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $102.58.

Key Headlines Impacting Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Baird updated Mirum’s valuation after the company reported a beat-and-raise on results, a development that supports upside and follows recent analyst price-target increases. Baird updates Mirum valuation
• Positive Sentiment: Multiple brokerages have raised targets/ratings in recent weeks (Morgan Stanley, HC Wainwright, Stifel, Robert W. Baird and others), reflecting confidence in revenue growth and the company’s lead product (maralixibat). These upgrades help underpin higher consensus price targets. MarketBeat analyst notes
• Neutral Sentiment: Company fundamentals: Mirum is a late-stage biopharma focused on rare cholestatic liver diseases; recent quarter showed strong revenue growth and an EPS beat, but the company remains loss-making on GAAP metrics and carries leverage. This context supports analyst optimism but also ongoing execution risk. Company profile and results
• Neutral Sentiment: Institutional activity shows modest position changes by funds (small buys/sells), not a clear directional institutional shift. Institutional holdings
• Negative Sentiment: Significant insider selling: several senior executives sold shares on Jan. 22 — CEO Christopher Peetz (7,098 shares), COO Peter Radovich (2,382), CFO Eric Bjerkholt (1,421), SVP Jolanda Howe (926) and insider Joanne Quan (multiple recent sales). The block of insider sales (each at ~\$93.33) reduces insider ownership and is likely weighing on sentiment and the stock today. Insider trades alert

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.